According to the company, the tests on humans showed a level of antibodies comparable to that of patients recovered from the disease.

Sanofi stated that all control groups involved in the trials showed a favorable immune response.

The company CEO Olivier Bogillot considered that the results are very important and expressed satisfaction for showing ‘determination’.

Also according to the company, the third phase of the trial on humans, which would involve tens of thousands of subjects, might commence in the next few days, once the authorities have green-lighted it.

As for the variants of the vaccine, Sanofi announced one based on the classic Wuhan strain, and another one on the strain identified in South Africa.

The company did not offer details on the project delays; however it confirmed it is in touch with potential buyers in the European Union.

ef/llp/mem/wmr